Lincoln Pharmaceuticals reported strong operational and financial performance for the quarter ended June 30, 2026. The company posted a consolidated net profit of ₹36.23 crore in Q1 FY27, up 30.90% from ₹27.68 crore in Q1 FY26. Total income increased 19.02% year-on-year to ₹201.55 crore, compared with ₹169.34 crore in the corresponding quarter last year. EBITDA also rose 32.29% to ₹51.70 crore, compared with ₹39.08 crore in Q1 FY26. The company reported an EPS of ₹18.09 per share.
Targeting ₹1,000 Crore Revenue
The company aims to achieve ₹1,000 crore in revenue over the next three years, supported by an annual growth target of 15–18%. Growth is expected across key therapeutic segments, including cardiac, diabetes, dermatology and ENT. At the same time, Lincoln Pharmaceuticals plans to expand its domestic and international presence by leveraging its manufacturing capabilities and product pipeline.
The company also remains focused on strengthening its presence across regulated and semi-regulated markets. It currently exports to more than 60 countries across East and West Africa, Central and North America, Latin America and Southeast Asia, and aims to expand its footprint to 90 countries within the next two to three years.
Expanding Global Market Presence
Lincoln Pharmaceuticals has recently entered the Canadian market and secured approvals from Australia’s TGA and EU-GMP, supporting its plans for further international expansion. CRISIL Ratings has also reaffirmed its ‘CRISIL A/Stable/CRISIL A1’ ratings on the company’s bank facilities. The ratings reflect its experienced promoters, established market position and healthy financial profile, although the company continues to face working-capital, regulatory and competitive challenges.
Manufacturing and Product Portfolio
Lincoln Pharmaceuticals operates a state-of-the-art manufacturing facility at Khatraj, Ahmedabad, Gujarat, which complies with international quality and regulatory standards. The facility holds certifications including EU-GMP, TGA, WHO-GMP, ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018. The company has developed more than 600 formulations across 15 therapeutic areas, with a portfolio spanning anti-infectives, respiratory care, gynaecology, cardiovascular and CNS therapies, antibacterial and antidiabetic medicines, and antimalarial products. In addition, Lincoln Pharmaceuticals has filed more than 25 patent applications and secured seven patents. Its broader portfolio includes more than 1,700 registered products, with another 700 products currently under development.
Focus on Sustainable Growth
Munjal Patel, Director, Lincoln Pharmaceuticals, said the company has started FY27 with a focus on sustaining its growth momentum while strengthening its core business areas. He highlighted the company’s plans to expand across domestic and international markets while improving operational efficiency, broadening its product portfolio and maintaining disciplined execution. As per the press release, with a focus on innovation, global expansion and financial discipline, Lincoln Pharmaceuticals aims to cross the ₹1,000 crore revenue milestone while maintaining a debt-free balance sheet and delivering sustainable growth.
